Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (648 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 09 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 50 history starts 18 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Nippon India Index Fund - BSE Sensex |
|---|---|
| 09 Jan 2013 | ₹100.00 |
| 27 Feb 2014 | ₹108.13 |
| 18 Apr 2015 | ₹145.70 |
| 05 Jun 2016 | ₹138.23 |
| 24 Jul 2017 | ₹168.01 |
| 11 Sep 2018 | ₹196.83 |
| 31 Oct 2019 | ₹213.02 |
| 18 Dec 2020 | ₹251.68 |
| 05 Feb 2022 | ₹316.68 |
| 26 Mar 2023 | ₹314.25 |
| 14 May 2024 | ₹404.51 |
| 02 Jul 2025 | ₹467.36 |
| 20 Aug 2026 | ₹439.20 |
| Metric | Nippon India · Direct · Bonus NAV ₹42.21 Very High risk ★★☆☆☆ | Category median Index Funds · 648 funds |
|---|---|---|
| -4.50% | +5.58% | |
| +7.06% | +8.01% | |
| +8.06% | +9.10% | |
| +11.70% | +11.55% | |
| +11.49% | +7.61% | |
| +5.97% | — | |
| +12.67% | +11.67% | |
| +13.21% | +13.31% | |
| +12.79% | +12.77% | |
| Risk | ||
| 13.22% | 13.65% | |
| 0.04 | 0.18 | |
| 0.06 | 0.26 | |
| -37.16% | -16.10% | |
| Nifty 50 | — | |
| -0.78% | +0.65% | |
| 0.99 | 1.00 | |
| 98.5% | 102.2% | |
| 103.4% | 97.7% | |
| 0.22% | 0.35% | |
| ₹908.92Cr | ₹182.17Cr | |
| None | — | |
| None | — | |
| — | — | |
| ₹5.00K | — | |
| — | 36% | |
| Himanshu Mange | — | |
| 09 Jan 2013 | — | |
| — | — | |
| — | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.